Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
type: MedicalStudy
description: A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
status: TERMINATED
study design: INTERVENTIONAL
phase: PHASE1
start date: 2003-12
end date: 2005-09
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00113048
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Genzyme, a Sanofi Company
study subject: Hematologic Malignancies
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: TERMINATED
keywords: Hematologic Malignancies

AI Analytics
type: Organization